高盛会谈：AI 如何推动药物研发——Xaira Therapeutics 公司 Marc Tessier Lavigne20260131 摘要 A 级人才吸引 A 级人才，提高人才标准至关重要，如洛克菲勒大学宁缺 毋滥的教职招聘策略和斯坦福大学 140 年前确立的高标准文化，均体现 了人才质量对机构发展的深远影响。 大学在人才培养中扮演关键角色，尤其在识别和培养具备解决重大问题 驱动力和智慧的人才方面。大学是汇聚、培育未来领袖并助力其开启职 业生涯的不可或缺的平台。 Zynerba Therapeutics 利用人工智能革新药物研发，通过高质量数据 积累，减少对传统湿实验的依赖，旨在缩短研发周期、提高成功率，并 已筹集 10 亿美元资金支持该愿景。 Zynerba Therapeutics 采取全面策略，同时攻克分子靶点选择、药物 设计及患者表征三大领域，通过 AI 技术与自主研发的高通量生物学系统 生成海量数据，形成差异化竞争优势。 Zynerba Therapeutics 作为一家利用人工智能革新药物研发与发现过程的 新兴公司，有何独特之处？ 药物研发过程本质上效率低下，目前仍依赖大量经验和直觉，存在高失 ...

Investment Rating - The investment rating for the company is maintained as "Buy" with a target price of HKD 19.25 [1][4]. Core Insights - The company has announced a significant overseas transaction involving its long-acting peptide drug metabolism AI discovery platform, which includes a USD 1.2 billion upfront payment, up to USD 3.5 billion in development milestones, and up to USD 13.8 billion in potential sales milestones, along with a double-digit percentage royalty on net sales to AstraZeneca [1][2]. - This transaction is the largest among domestic pharmaceutical companies in the year and is comparable to the 2015 upfront payment scale between 3SBio and Pfizer [1]. - The company is expected to benefit from the upfront payment, leading to a high apparent year-on-year growth in net profit for 2026 [1][3]. Summary by Sections Transaction Details - The deal with AstraZeneca includes a USD 1.2 billion upfront payment, a maximum of USD 3.5 billion in development milestones, and a maximum of USD 13.8 billion in potential sales milestones, along with a double-digit percentage royalty on net sales [2]. - The platform includes core assets such as GIPR/GLP-1R (monthly formulations) and three preclinical weight loss pipelines with different mechanisms of action [2]. Platform Mechanism - The company possesses a globally leading liposome platform, and the fluid crystal technology allows for long-term release of active ingredients, enabling monthly or longer dosing [2]. Pipeline Potential - The company’s pipeline includes significant projects such as EGFR ADC, which is expected to enter Phase III clinical trials both domestically and internationally, and other oncology and autoimmune therapies [3]. - The company is focusing on filling gaps in its wild-type lung squamous carcinoma layout with PD-1/IL-15 and has ADC pipelines targeting HER3, B7H3, DLL3, among others [3]. Profit Forecast and Valuation - The company’s net profit is projected to be RMB 4.45 billion in 2025 and RMB 8.46 billion in 2026, with corresponding EPS of RMB 0.39 and RMB 0.73 [4][9]. - The target price is set at HKD 19.25, reflecting a 24x PE for 2026, with adjustments made based on the anticipated impact of product procurement [4][11].

今年以来首药控股已公布的国际专利申请3个。结合公司2025年中报财务数据，2025上半年公司在研发 方面投入了1.08亿元，同比增1%。 数据来源：企查查 以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成 投资建议。 图片来源：世界知识产权组织（WIPO） 证券之星消息，根据企查查数据显示首药控股（688197）公布了一项国际专利申请，专利名为"一种药 物制剂组合物及其制备方法"，专利申请号为PCT/CN2025/110506，国际公布日为2026年1月29日。 专利详情如下： ...

Investment Rating - The report maintains a positive outlook on Takeda Pharmaceutical, indicating that there is more potential to be unlocked in the future [3][4]. Core Insights - Takeda reported a 4.2% year-on-year revenue growth for Q3 FY2026, aligning with market expectations. Net profit surged by 335.7% due to improved profit margins and reduced non-operating costs, exceeding market forecasts [4]. - The company anticipates multiple late-stage pipeline products to be launched starting in FY2026, including Zasocitinib, which has shown competitive results in clinical trials for moderate to severe plaque psoriasis [5][6]. - The strong performance of Entyvio, with an 18% increase in sales to 265 billion yen, was noted, although the decline in Vyvanse sales by 42% partially offset this growth [4]. Summary by Sections Financial Performance - For Q3 FY2026, Takeda's revenue reached 1.192 trillion yen, a 4.2% increase year-on-year, with net profit rising to 104 billion yen, a 335.7% increase [4]. - The company maintained its full-year guidance for FY2026 despite fluctuations in product sales [4]. Pipeline Developments - Takeda's late-stage assets, including Zasocitinib and Dacomitinib, are expected to be submitted for new drug applications in FY2027, with promising clinical trial results reported [5][6]. - The company has also submitted a new drug application for rusfertide and plans to enter the application phase for oveporexton shortly [5]. Market Position - Takeda operates in various therapeutic areas, including gastroenterology, rare diseases, plasma-derived therapies, oncology, and neuroscience [8]. - The company’s revenue distribution shows that 29.6% comes from gastroenterology, 22.5% from plasma-derived therapies, and 16.4% from rare blood diseases, with significant contributions from the Americas [10].

Group 1 - The company expects to record an unaudited net loss attributable to the parent company of approximately RMB 120 million to RMB 180 million for the fiscal year ending December 31, 2025, compared to an audited net profit of RMB 39.73 million in 2024 [1] - The company is actively advancing its R&D projects, with R&D expenditure accounting for an increasing proportion of revenue. The Phase III clinical trial for the FDA018 antibody-drug conjugate has exceeded its enrollment target, with over 350 cases enrolled [1] - The company’s subsidiary is supporting the industrialization of antibody-drug conjugates (ADC) by conducting commercial-scale production technology transfers and process validations [1] Group 2 - The company’s photodynamic drug development projects are progressing as planned, with the application for the registration of a powder for oral solution of Amifostine for intraoperative visualization of high-grade gliomas accepted [2] - The company’s R&D expenditure for the reporting period was approximately RMB 350 million [2] - The product Liposomal Doxorubicin was included in the national centralized procurement directory for the first time in 2024, leading to a corresponding adjustment in sales strategy and a decrease in profit contribution of approximately RMB 100 million compared to the same period last year [2]

Group 1 - The company anticipates a total profit loss of 291.82 million yuan for the year 2025, with a net profit attributable to the parent company expected to be -292.20 million yuan, and a net profit after deducting non-recurring gains and losses projected at -304.41 million yuan [3] - The expected operating revenue for 2025 is 37.25 million yuan, which is below 100 million yuan [3] - The company reported a total profit loss of 240.20 million yuan for the year 2024, with a net profit attributable to the parent company also at -240.20 million yuan [5] Group 2 - The significant changes in performance for 2025 are primarily influenced by the intensity of research and development (R&D) investment and the composition of revenue [7] - The company is advancing multiple core clinical projects, including D-0502, D-2570, and D-0120, which are in various stages of clinical trials [7] - The company has made key progress in its preclinical pipeline with two innovative candidates, YF087 and YF550, showing promising anti-tumor potential [7][8] Group 3 - The company maintains high levels of R&D investment, but its current revenue mainly comes from licensing and collaboration, which varies from year to year [8] - The income from technology licensing and collaboration is currently insufficient to cover costs and expenses, leading to expected continued losses in 2025 [8] - Despite the anticipated losses, the company's core business and competitive strengths have not experienced significant adverse changes [8]

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific innovation and advanced manufacturing [2] Group 1: Investment Plans - The investment will enhance AstraZeneca's capabilities in cell therapy and radiolabeled drugs, contributing to a diverse product pipeline for cancer, blood diseases, and autoimmune diseases [3] - This investment follows a previous commitment of up to $2.5 billion to establish a strategic R&D center in Beijing, marking AstraZeneca's sixth global and second Chinese R&D center [2] Group 2: R&D and Innovation - As of January 2023, AstraZeneca has invested over $1.8 billion in China and plans to launch 20 global innovative drugs by the end of 2030 [3] - The company currently has over 200 projects in its Chinese R&D pipeline, with 10-15 new projects added annually [3] Group 3: Strategic Importance - AstraZeneca's CEO emphasized that this investment marks a new chapter in the company's development in China, recognizing the country's role in scientific innovation and global public health [2]

Core Viewpoint - AstraZeneca plans to invest over 100 billion RMB in China by 2030 to expand its pharmaceutical production and R&D capabilities, leveraging China's scientific and manufacturing strengths to deliver innovative therapies to patients globally [3][4]. Investment Plans - The investment will cover the entire value chain from drug discovery to clinical development and manufacturing, enhancing AstraZeneca's capabilities in cell therapy and radiolabeled drugs [4]. - This commitment follows a previous investment of up to 2.5 billion USD announced in March 2022 for establishing a strategic R&D center in Beijing, marking AstraZeneca's second such center in China [3]. R&D and Product Pipeline - Since 2023, AstraZeneca has invested over 1.8 billion USD to strengthen its manufacturing in China and plans to launch 20 global innovative drugs by the end of 2030 [4]. - As of January 2024, AstraZeneca's R&D pipeline in China includes over 200 projects, with 10-15 new projects added annually [4].

2025年度，公司业绩变化主要受到研发投入强度与营收构成的共同影响。随着研发管线的扎实推进，多 个核心临床项目已进入关键阶段，并取得积极进展，研发投入维持在较高水平：口服选择性雌激素受体 降解剂(SERD)D0502正在国内开展二线治疗注册III期临床试验;TYK2抑制剂D-2570已启动多个自身免疫 性疾病领域的临床探索，包括正在国内开展的溃疡性结肠炎II期临床试验、银屑病注册III期临床试验， 以及在美国开展的I期临床试验等;URAT1抑制剂D-0120在美国开展的联合用药II期临床试验于报告期内 完成随访，预计将于2026年第一季度完成全部研究工作。 益方生物(688382.SH)发布2025年年度业绩预亏公告，预计2025年度实现归属于母公司所有者净亏损2.92 亿元。 2025年，公司临床前管线转化也取得关键进展，两款具有创新性的临床前候选药物，WRN抑制剂 YF087和KIF18A抑制剂YF550在多项临床前研究中展现出优秀的抗肿瘤潜力，目前正在开展IND支持性 研究，为后续进入临床阶段做准备;与此同时，公司持续投入早期研发，包括其他候选药物的开发、创 新技术平台建设以及药物的早期发现，为长期发展 ...

七味防己黄芪颗粒处方由天津中医药大学结合中医经典理论和临床实践，在"防己黄芪汤"基础上进行配 伍化裁而来。该项目由青春宝与天津中医药大学等单位合作研发，并拥有核心知识产权。 格隆汇1月29日丨上海医药(02607.HK)发布公告，近日，公司下属正大青春宝药业有限公司(以下简 称"青春宝")研发的"七味防己黄芪颗粒"收到国家药监局核准签发的《药物临床试验批准通知书》。 ...